Preterm infants have a high risk of neonatal white matter injury (WMI). WMI leads to reduced myelination, inflammation, and clinical neurodevelopmental deficits for which there are no effective treatments. Ionotropic glutamate receptor (iGluR) induced excitotoxicity contributes to oligodendrocyte (OL) lineage cell loss and demyelination in brain models of neonatal and adult WMI. Here, we hypothesized that simulated ischemia (oxygen‑glucose deprivation) damages white matter via activation of iGluR signaling, and that iGluR inhibition shortly after WMI could mitigate OL loss, enhance myelination, and suppress inflammation in an ex vivo cerebellar slice model of developing WMI. Inhibition of iGluR signaling by a combined block of AMPA and NMDA receptors, shortly after simulated ischemia, restored myelination, reduced apoptotic OLs, and enhanced OL precursor cell proliferation and maturation as well as upregulated expression of transcription factors regulating OL development and remyelination. Our findings demonstrate that iGluR inhibition post‑injury alleviates OL lineage cell loss and inflammation and promotes myelination upon developing WMI. The findings may help to develop therapeutic interventions for the WMI treatment.
Mohamed A. Al-Griw, Michael G. Salter, Ian C. Wood(1-2021)

Accumulating evidence indicates the role of endocrine disruptor bisphenol A (BPA) in many pathological conditions. Histone deacetylase (HDAC) inhibition has potential for the treatment of many diseases/abnormalities. Using a mouse BPA exposure model, this study investigated the hepatoprotective effects of the Food and Drug Administration–approved HDAC2 inhibitor valproic acid (VPA) against BPA-induced liver pathology. We randomly divided 30 adult male Swiss albino mice (8 weeks old; N = 6) into five groups: group 1, no treatment (sham control (SC)); group 2, only oral sterile corn oil (vehicle control (VC)); group 3, 4 mg/kg/day of oral BPA (single dose (BPA group)); group 4, 0.4% oral VPA (VPA group); and group 5, oral BPA + VPA (BPA + VPA group). At the age of 10 weeks, the mice were euthanized for biochemical and histological examinations. BPA promoted a significant decrease in the body weight (BW), an increase in the liver weight, and a significant increase in the levels of liver damage markers aspartate aminotransferase and alanine aminotransferase in the BPA group compared to SC, as well as pathological changes in liver tissue. We also found an increase in the rate of apoptosis among hepatocytes. In addition, BPA significantly increased the levels of oxidative stress indices, malondialdehyde, and protein carbonylation but decreased the levels of reduced glutathione (GSH) in the BPA group compared to SC. In contrast, treatment with the HDAC2 inhibitor VPA significantly attenuated liver pathology, oxidative stress, and apoptosis and also enhanced GSH levels in VPA group and BPA + VPA group. The HDAC2 inhibitor VPA protects mice against BPA-induced liver pathology, likely by inhibiting oxidative stress and enhancing the levels of antioxidant-reduced GSH.
Mohamed A. Al-Griw, Zaynab Osama Alshibani, Rabia Omar abdullah Alghazeer, Mohamed Elhensheri, Refaat. M. Tabagh, Areej A. Eskandrani, Wafa S. Alansari, Mahmoud M. Habibulla, Ghalia Shamlan(6-2022)

Opinion Cough in kids less than 6yrs old whether being with sputum i.e. wet or without i.e. dry and parental asking about any medicine stopping this symptom certainly if being dry i.e. irritating and disturbing sleep. So most studies being done on this subject proved the following: a) It is not wise to suppress cough because it is natural defense mechanism to expel infected mucus i.e. sputum out of the body and clearing the airways to improve oxygenation so never to prescribe antitussive i.e. cough suppressant. b) sputum mucolytic agents and there are many agents their purpose to liquify it and get it watery to be easy expectorated again studies proved that the best muculytic agent is Good Hydration so no need to use except where there is a mucus retention in the lungs like case of brocheictasis. c) WHO recommendation made about 6 yrs back was never to prescribe any cough medicine whether antitussive or mucolytic to kids less than 6 yrs old. Myself and since about 10 years I had not prescribed any cough suppressant to children despite of age but if kids older than 6 years old I do prescribe mucolytic agent made certainly for kids like amydramine syrup which contains antihistamine diphenhydramine and without restrictions. In kids less than 6yrs old again I do prescribe mucolytic made for kids like soolan or Amydramine pediatric syrup in trial to hit 2 birds which are sedating and antihistamine effects and satisfying anxious parents and it does work almost in all cases arabic 6 English 32
Hisham Mukhtar Alhaashimi Alrabty(5-2017)